QualityDipStocks / Health Care · Biotech
Vir Biotechnology VIR
Outside our quality screen, so we don’t track its dips. It’s 8% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $10.72price +3%
- Off 52-wk high
- −8%
- Risk vs market
- Highbeta 1.77
52-week range 86% of the way from its 52-week low to its high
Price $11.00Market Value $10.72
3 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for VIR: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much VIR moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings much more than the market, and its own price swings are 5.0× the S&P 500’s.
- Beta vs S&P 500
- 1.77
- Volatility
- 64% vs 13% SPY
- Correlation SPY
- 0.35
- Correlation QQQ
- 0.31
How it ranks
Where VIR stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 3 measures
- Free cash flow yield−11% · free cash flow vs market capLowest 3%of 1,690
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Operating margin−92% · of sales kept as operating profitLowest 1%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $10.72
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
ProfitabilityOperating margin widened to 51.6% in FY2022 from −43.3% in FY2023 (SEC filings).
ProfitabilityGross margin widened to 100.0% in FY2025 from 96.8% in FY2023 (SEC filings).
ValuationPrice / book of 1.9×, below the 4.8× median for the 291 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$204M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $252M over the last 12 months (net income, SEC filings).
GrowthSales shrank 65% a year from FY2022 to FY2025.
Cash returnsShare count up 22.0% in a year: existing holders are being diluted.
QualityDoesn’t pass our quality screen: no positive free cash flow.
All fundamentals
FCF yield -10.7% · ROE -26%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −10.7%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 6.27×
- Price / book
- 1.93×
- Market cap
- $1.9Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $303M
- Sales growth, 12 months
- n/an/m: revenue a year ago near zero
- Sales growth, 3 yrs
- −65.1%/yrfrom FY2022
- Diluted EPS, 12 months
- −$1.77
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$252M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 100.0%
- Operating margin
- −92.4%
- Net margin
- −83.0%
- FCF margin
- −67.1%
- Return on equity
- −26%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $529M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$204M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +22.0%diluted shares vs a year ago
- Stock-based comp
- $47M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Vir Biotechnology’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.2B · Sales +19582%
- Free cash flow, 12 months−$0.2B
- Free-cash-flow yield-10.7%
- Gross margin−59%
- Operating margin31%
- Return on invested capital14%
- Return on equity−26%
- Sales growth (latest quarter vs year-ago quarter)+19582%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $11.00
- 52-wk lowlowest close, 1 year$5.12−53.5%
- Market Valueavg paid since Aug 5$10.72−2.5%
- PriceMon Nov 2 close$11.00you are here
- 52-wk highhighest close, 1 year$11.93+8.5%
Momentum & 52-week range
RSI 50 · 5 days −0.4%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, after the close
- Consensus EPS($0.80)
- Year-ago EPS($1.17)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
VIR is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Vir Biotechnology in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Biotech
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.